NEW YORK, April 30, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding CommVault Systems, Inc. (NASDAQ: CVLT), Synaptics Inc. (NASDAQ: SYNA), Cerner Corporation (NASDAQ: CERN), Altera Corporation (NASDAQ: ALTR) and KLA-Tencor Corporation (NASDAQ: KLAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1864-100free.
--
CommVault Systems, Inc. Analyst Notes
On April 25, 2014, the stock of CommVault Systems Inc. (CommVault) plunged to its lowest level in 52 weeks after the Company released its Q4 FY 2014 financial results, showing revenues grew at a slower-than-expected pace during the quarter, while net income declined. The Company's revenues during the quarter came in at $156.8 million, up 13.4% YoY. On average, analysts polled by Reuters expected revenues of $160.2 million. CommVault's net income during the quarter declined to $15.7 million, or $0.32 per diluted share, from $17.0 million, or $0.35 per diluted share, in Q4 FY 2013. Adjusted diluted net income of the Company during the quarter was $0.52 per share, which surpassed the Reuters' analyst consensus estimate of $0.47. CommVault Chairman, President and CEO stated that strong EMEA results were offset by lower than forecasted results in the Americas, which negatively impacted license revenue growth for the quarter. The full analyst notes on CommVault are available to download free of charge at:
http://www.analystsreview.com/1864-CVLT-30Apr2014.pdf
--
Synaptics Inc. Analyst Notes
On April 24, 2014, Synaptics (Synaptics Inc.) reported financial results for Q3 FY 2014 (period ended March 31, 2014). The Company's revenues during the quarter jumped 25.1% YoY to $204.3 million, as mobile products revenue, which includes all touchscreen, video display, and applicable fingerprint ID products, increased 44% YoY. Weighed down by acquisition costs, the Company posted net loss of $40.1 million, or $1.12 per diluted share, during the quarter, compared to net income of $36.4 million, or $1.07 per diluted share, in Q3 FY 2013. The Company, in October 2013, acquired Validity Sensors Inc. to enter the fingerprint ID market. Synaptics stated that Fingerprint ID business was accretive to its non-GAAP results ahead of schedule. Its adjusted diluted EPS of $0.63 was at the high-end of guidance range, and well ahead of Reuters' analyst consensus estimate of $0.57 per share. Synaptics expect revenue growth of 37-40% YoY for full year FY 2014. The full analyst notes on Synaptics are available to download free of charge at:
http://www.analystsreview.com/1864-SYNA-30Apr2014.pdf
--
Cerner Corporation Analyst Notes
On April 24, 2014, Cerner Corporation (Cerner) announced results for Q1 2014. The Company posted a growth of 15.4% YoY in revenues at $784.8 million. Cerner's net income during the quarter increased to $119.5 million, or $0.34 per diluted share, from $110.0 million, or $0.31 per diluted share, in Q1 2013. Cerner stated that its bookings reached an all-time first quarter high of $910.2 million, reflecting an increase of 14% YoY. Looking ahead, the Company expects Q2 2014 revenues to range between $790 million and $830 million. Also, Q2 2014 adjusted diluted EPS is to be seen in the range of $0.39 and $0.40. The full analyst notes on Cerner are available to download free of charge at:
http://www.analystsreview.com/1864-CERN-30Apr2014.pdf
--
Altera Corporation Analyst Notes
On April 24, 2014, Altera Corporation (Altera) released its Q1 2014 financial results showing net sales growth of 12.3% YoY to $461.1 million, as stronger than anticipated Chinese LTE deployments drove wireless sales. Altera stated that new product sales during the quarter increased 39% YoY, while mainstream product sales declined 12% YoY. The Company's net income during the quarter declined to $116.5 million, or $0.37 per diluted share, from $120.2 million, or $0.37 per diluted share, in Q1 2013. On average, analysts polled by Reuters expected the Company to report earnings per share of $0.32. Looking ahead to Q2 2014, the Company expects sales to grow 2-6%. Altera has also declared a quarterly cash dividend of $0.15 per share, to be paid on June 2, 2014 to stockholders of record on May 12, 2014. On April 25, 2014, the Company's stock declined by 3.08%, closing the trading session at $33.09. The full analyst notes on Altera are available to download free of charge at:
http://www.analystsreview.com/1864-ALTR-30Apr2014.pdf
--
KLA-Tencor Corporation Analyst Notes
On April 24, 2014, KLA-Tencor Corporation (KLA-Tencor) announced financial results for Q3 FY 2014 (period ended March 31, 2014). KLA-Tencor generated revenues of $832 million in Q3 FY 2014, up 18.0% sequentially and 14.1% YoY, beating the Reuters' consensus estimate of $822.64 million. Net income during the quarter increased to $203.6 million, or $1.21 per diluted share, from $166.4 million, or $0.98 per diluted share, in Q3 FY 2013. The adjusted diluted net income of the Company was $1.23 per share, compared to analyst consensus estimate of $1.12. On April 25, 2014, shares of KLA-Tencor declined 7.13% and ended the trading session at $62.91 with a trading volume of 4.48 million. The full analyst notes on KLA-Tencor are available to download free of charge at:
http://www.analystsreview.com/1864-KLAC-30Apr2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
